Literature DB >> 24639019

Oral cancer: current status of molecular biology and treatment strategy.

Tadaaki Kirita1.   

Abstract

Entities:  

Mesh:

Year:  2014        PMID: 24639019     DOI: 10.1007/s10147-014-0682-6

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


× No keyword cloud information.
  5 in total

1.  Preoperative concurrent chemoradiotherapy for stages II-IV oral squamous cell carcinoma: a retrospective analysis and the future possibility of this treatment strategy.

Authors:  T Kirita; Y Yamanaka; Y Imai; N Yamakawa; K Aoki; Y Nakagawa; T Yagyuu; M Hasegawa
Journal:  Int J Oral Maxillofac Surg       Date:  2012-02-21       Impact factor: 2.789

2.  Organ preservation with daily concurrent chemoradiotherapy using superselective intra-arterial infusion via a superficial temporal artery for T3 and T4 head and neck cancer.

Authors:  Kenji Mitsudo; Toshio Shigetomi; Yasushi Fujimoto; Hiroaki Nishiguchi; Noriyuki Yamamoto; Hiroki Furue; Minoru Ueda; Yoshiyuki Itoh; Nobukazu Fuwa; Iwai Tohnai
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-06-03       Impact factor: 7.038

3.  Head and neck cancer incidence trends in young Americans, 1973-1997, with a special analysis for tongue cancer.

Authors:  Stimson P Schantz; Guo-Pei Yu
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2002-03

Review 4.  Oral cancer in India: an epidemiologic and clinical review.

Authors:  R Sankaranarayanan
Journal:  Oral Surg Oral Med Oral Pathol       Date:  1990-03

Review 5.  Epigenetic and genetic alterations-based molecular classification of head and neck cancer.

Authors:  Zhien Feng; Qin Xu; Wantao Chen
Journal:  Expert Rev Mol Diagn       Date:  2012-04       Impact factor: 5.225

  5 in total
  1 in total

1.  Ginsenoside Rb3 Alleviates the Toxic Effect of Cisplatin on the Kidney during Its Treatment to Oral Cancer via TGF-β-Mediated Mitochondrial Apoptosis.

Authors:  Wen-Jie Wu; Yu-Fang Tang; Shuang Dong; Jie Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2021-01-16       Impact factor: 2.629

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.